Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Analysis of the Impact of Body Mass Index (BMI) on the Durability of Response in Patients with Aplastic Anemia Treated with Weight-Adjusted Horse Anti-Thymocyte Globulin (hATG)

Jeanette Walter, Benjamin Rolles, Yannic Schumacher, Frauke Theis, Leo Hansmann, Daniel Heudobler, Markus Radsak, Michael Heuser, Julia-Annabell Georgi, Jörg Chromik, Beatrice Drexler, Jörg Schubert, Kim Kricheldorf, Susanne Isfort, Jens Panse, Tim H. Brümmendorf, Fabian Beier

Blood (2023) 142 (Supplement 1): 5641.

https://doi.org/10.1182/blood-2023-183075

Published: 2023

Journal Articles

Factor B Inhibition with Oral Iptacopan Monotherapy Demonstrates Sustained Long-Term Efficacy and Safety in Anti-C5-Treated Patients (pts) with Paroxysmal Nocturnal Hemoglobinuria (PNH) and Persistent Anemia: Final 48-Week Results from the Multicenter, Phase III APPLY-PNH Trial

Blood (2023) 142 (Supplement 1): 571.

https://doi.org/10.1182/blood-2023-180780

Published: 2023

Journal Articles

Double-Blind, Placebo Controlled, Randomized, Multicenter, Phase II Study to Assess the Efficacy of the High Affinity CXCR4 Inhibitor BL-8040 As Addition to Consolidation Therapy in AML By the SAL and OSHO Leukemia Study Groups

Sonia Jaramillo Segura, Maxi Wass, Judith Schaffrath, Kathrin Rieger, Axel Nogai, Mathias Haenel, Regina Herbst, Friedrich Stoelzel, Christoph Röllig, Edgar Jost, Richard F. Schlenk, Richard Noppeney, Christian H. Brandts, Utz Krug, Katharina S. Goetze, Sebastian Buske, Axel Florschütz, Jörg Schubert, Bernhard Opitz, Martin Mohren, Eva Eßeling, Stephan von Witzendorff, Marion Subklewe, Martin Kaufmann, Norbert Frickhofen, Christian W Scholz, Kerstin Schäfer-Eckart, Volker Kunzmann, Martin Schmidt-Hieber, Herbert G. Sayer, Andreas Rank, Philipp Hemmati, Frank Schueler, Simone Kowoll, Marina Scheller, Jörg Steighardt, Bayram Edemir, Lutz Peter Mueller, Irit Gliko-Kabir, Beatrice Ludwig-Kraus, Sabine Edemir, Ella Sorani, Mascha Binder, Abi Vainstein, Shaul Kadosh, Cora Gromann, Andreas Wienke, Claudia D. Baldus, Uwe Platzbecker, Hubert Serve, Martin Bornhaeuser, Christian Junghanss, Carsten Mueller-Tidow

Blood (2022) 140 (Supplement 1): 3338–3340.

https://doi.org/10.1182/blood-2022-166748

Published: 2022

Journal Articles

In Patients with Relapsed/Refractory AML Sequential Conditioning and Immediate Allogeneic Stem Cell Transplantation (allo-HCT) Results in Similar Overall and Leukemia-Free Survival Compared to Intensive Remission Induction Chemotherapy Followed By Allo-HCT: Results from the Randomized Phase III ASAP Trial

Blood (2022) 140 (Supplement 1): 9–11.

https://doi.org/10.1182/blood-2022-159962

Published: 2022

Journal Articles

Comparing the Prognostic Significance of Early Predictors of Survival in Chronic Myeloid Leukemia (CML) Treated with Imatinib - an Analysis of the Randomized CML-Study IV

Blood (2014) 124 (21): 156.

https://doi.org/10.1182/blood.V124.21.156.156

Published: 2014

Journal Articles

Achievement Of a MR 5.0 Within the Randomized CML-Study IV: Feasibility, Differences Between Treatment Arms, and Prognostic Implications

Blood (2013) 122 (21): 4008.

https://doi.org/10.1182/blood.V122.21.4008.4008

Published: 2013

Journal Articles

Optimizing Early Prediction Of Outcome In CML Using The Exact Decline Of BCR-ABL Transcript Levels Within 3 Months Of Imatinib Treatment As a Prognostic Marker

Blood (2013) 122 (21): 253.

https://doi.org/10.1182/blood.V122.21.253.253

Published: 2013

Journal Articles

Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV

Blood (2011) 118 (26): 6760–6768.

https://doi.org/10.1182/blood-2011-08-373902

Published: 2011

Journal Articles

Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial

Blood (2010) 116 (14): 2438–2447.

https://doi.org/10.1182/blood-2010-03-275420

Published: 2010

Includes: Supplemental data

Journal Articles

Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation

Blood (2009) 114 (26): 5264–5270.

https://doi.org/10.1182/blood-2009-07-234880

Published: 2009

Journal Articles

Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria

Robert A. Brodsky, Neal S. Young, Elisabetta Antonioli, Antonio M. Risitano, Hubert Schrezenmeier, Jörg Schubert, Anna Gaya, Luke Coyle, Carlos de Castro, Chieh-Lin Fu, Jaroslaw P. Maciejewski, Monica Bessler, Henk-André Kroon, Russell P. Rother, Peter Hillmen

Blood (2008) 111 (4): 1840–1847.

https://doi.org/10.1182/blood-2007-06-094136

Published: 2008

Journal Articles

Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria

Peter Hillmen, Petra Muus, Ulrich Dührsen, Antonio M. Risitano, Jörg Schubert, Lucio Luzzatto, Hubert Schrezenmeier, Jeffrey Szer, Robert A. Brodsky, Anita Hill, Gerard Socié, Monica Bessler, Scott A. Rollins, Leonard Bell, Russell P. Rother, Neal S. Young

Blood (2007) 110 (12): 4123–4128.

https://doi.org/10.1182/blood-2007-06-095646

Published: 2007

Includes: Supplemental data

Journal Articles

Multicenter Phase II Trial of Patients with Refractory or Recurrent Multiple Myeloma with Oral Treatment of Thalidomide Combined with Oral Cyclophosphamide, Idarubicin and Dexamethasone.

Axel Glasmacher, MD, Thomas Moehler, MD, Hartmut Goldschmidt, MD, Thomas Geer, MD, Rolf Kleinschmidt, MD, Tobias Gaska, MD, Janssens Uwe, MD, Jorg Schubert, MD, Patrick Bruck, MD, Michael R. Clemens, MD, Wolfgang Bair, MD, Gernot Seipelt, MD, Michael Schleuning, MD, Corinna Hahn-Ast, PhD, Susanne Herz, Marie von Lilienfeld-Toal, MD, Ralf Naumann, MD, Marcus Gorschluter, MD, Ingo G.H. Schmidt-Wolf, MD

Blood (2007) 110 (11): 4825.

https://doi.org/10.1182/blood.V110.11.4825.4825

Published: 2007

NARROW

Analysis of the Impact of Body Mass Index (BMI) on the Durability of Response in Patients with Aplastic Anemia Treated with Weight-Adjusted Horse Anti-Thymocyte Globulin (hATG)

Factor B Inhibition with Oral Iptacopan Monotherapy Demonstrates Sustained Long-Term Efficacy and Safety in Anti-C5-Treated Patients (pts) with Paroxysmal Nocturnal Hemoglobinuria (PNH) and Persistent Anemia: Final 48-Week Results from the Multicenter, Phase III APPLY-PNH Trial

Double-Blind, Placebo Controlled, Randomized, Multicenter, Phase II Study to Assess the Efficacy of the High Affinity CXCR4 Inhibitor BL-8040 As Addition to Consolidation Therapy in AML By the SAL and OSHO Leukemia Study Groups

Comparing the Prognostic Significance of Early Predictors of Survival in Chronic Myeloid Leukemia (CML) Treated with Imatinib - an Analysis of the Randomized CML-Study IV

Achievement Of a MR 5.0 Within the Randomized CML-Study IV: Feasibility, Differences Between Treatment Arms, and Prognostic Implications

Optimizing Early Prediction Of Outcome In CML Using The Exact Decline Of BCR-ABL Transcript Levels Within 3 Months Of Imatinib Treatment As a Prognostic Marker

Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV

Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial

Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation

Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria

Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria

Multicenter Phase II Trial of Patients with Refractory or Recurrent Multiple Myeloma with Oral Treatment of Thalidomide Combined with Oral Cyclophosphamide, Idarubicin and Dexamethasone.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only